ABSTRACT:
There are many diagnostic and treatment obstacles associated with immune thrombocytopenia (ITP), an autoimmune disease that is becoming more and more common and is defined by platelet destruction and insufficient generation. Current ITP management often lacks real-time assessment and personalized data integration, impacting patient outcomes. This review highlights disruptive technologies poised to revolutionize ITP monitoring and diagnosis, addressing these limitations. Wearable devices and microsensors enable continuous, non-invasive platelet quantification and bleeding risk assessment. Point-of-care diagnostics and microfluidic devices expedite accessible testing, providing qualitative insights into platelet function. Artificial intelligence (AI) algorithms analyze comprehensive patient data integrating blood work, wearable information, and genetic predispositions to predict flares and customize treatment strategies, similar to successful AI applications in leukemia and breast cancer. These advancements promise earlier diagnosis, standardized treatment options, and enhanced data accessibility while potentially mitigating drug-induced thrombocytopenia (DITP). However, challenges including increased costs, regulatory concerns, and data privacy must be addressed for widespread implementation. This review contrasts current ITP diagnostic and therapeutic modalities with emerging technologies, emphasizing their transformative potential to improve patient outcomes through integrated, technology-driven solutions and highlighting the need for further research and clinician involvement.